首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CX3CL1 |
| Uniprot No | P78423 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-100aa |
| 氨基酸序列 | QHHGVTKCNI TCSKMTSKIP VALLIHYQQN QASCGKRAII LETRQHRLFC ADPKEQWVKD AMQHLDRQAA ALTRNG |
| 预测分子量 | 42 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CX3CL1(Fractalkine)重组蛋白的3篇代表性文献示例(内容为模拟概括，实际引用需查证原文)：
---
1. **文献名称**: *"Recombinant CX3CL1/Fractalkine promotes monocyte survival and induces chemotaxis in vitro"*
**作者**: Chandrasekar B, et al.
**摘要**: 研究报道了重组CX3CL1蛋白的制备及其在单核细胞趋化中的作用，证实其通过CX3CR1受体激活促进单核细胞迁移和存活，提示其在动脉粥样硬化等炎症疾病中的潜在机制。
---
2. **文献名称**: *"Recombinant fractalkine modulates microglial activation and protects neurons in Alzheimer's disease models"*
**作者**: Zujovic V, et al.
**摘要**: 通过体外和动物实验，发现重组CX3CL1蛋白可抑制β-淀粉样蛋白诱导的小胶质细胞过度激活，减少神经元凋亡，为神经退行性疾病的治疗提供新策略。
---
3. **文献名称**: *"Structural and functional characterization of soluble recombinant human CX3CL1"*
**作者**: Saita Y, et al.
**摘要**: 利用哺乳动物表达系统成功制备高纯度可溶性CX3CL1重组蛋白，并通过晶体结构解析揭示其与受体CX3CR1的结合域，为靶向药物开发奠定基础。
---
注：以上为示例性内容，实际文献需通过PubMed、Web of Science等平台检索确认详细信息及准确性。
CX3CL1. also known as fractalkine, is a unique chemokine characterized by its dual-function structure, combining features of both chemotactic cytokines and cell adhesion molecules. It exists in two forms: a membrane-bound glycoprotein that mediates leukocyte adhesion through its chemokine domain and mucin-like stalk, and a soluble form released via proteolytic cleavage, which acts as a chemoattractant. This protein selectively interacts with its sole receptor, CX3CR1. predominantly expressed on monocytes, natural killer cells, and microglia.
Recombinant CX3CL1 protein is produced using genetic engineering techniques, typically through expression in mammalian cell systems (e.g., HEK293 cells) or prokaryotic systems like E. coli. The recombinant form preserves the functional chemokine domain (amino acids 1-76), crucial for receptor binding and signaling. Production involves codon optimization, affinity tag incorporation for purification, and rigorous quality control to ensure proper folding and bioactivity.
In research, recombinant CX3CL1 serves as a critical tool for studying neuro-immune interactions, particularly in neuroinflammatory conditions and neurodegenerative diseases like Alzheimer's. It helps elucidate mechanisms of leukocyte migration, microglial activation, and neuronal survival. The protein's role in atherosclerosis and cancer metastasis is also actively investigated, with therapeutic applications explored in preclinical models. Recent studies emphasize its paradoxical functions in neuroprotection versus neurotoxicity, depending on cellular context and disease stage. Researchers must consider species-specific variations and post-translational modifications when selecting recombinant versions for experimental models.
×
